Waters Corporation [NYSE:WAT]: Democratizing Biotechnology with Advanced Analytical Tools

Andy Craze, Senior Director, Informatics Business
Modern biological science is intimately entwined with, and profoundly dependent upon, specialized analytical methodology. Moreover the onset of bioinformatics, techniques to understand and organize molecular level information, have increased tremendously. “However, the heterogeneity and complexity of contemporary biopharmaceuticals add a level of complication when those molecules need to be profiled in a simplified way,” observes Andy Craze, Senior Director, Informatics Business, Waters Corporation [NYSE:WAT]. Headquartered in Milford, MA, Waters Corporation develops innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance in a broad range of pharmaceutical related industries. Waters creates business advantages for laboratory-dependent organizations by delivering Ultra Performance Liquid Chromatography (UPLC), High Performance Liquid Chromatography (HPLC) and chemistry products, Mass Spectrometry (MS) systems and laboratory informatics solutions.

As an example of an application use for Waters' technology, Craze foresees that biosimilars—identical copies of an original product— represent a growing demand for provision of sufficient analytical and biological evidence between innovator and biosimilar candidates. For biotech organizations challenged to deploy high-resolution analytics across the innovative biotherapeutic or biosimilar development process, Waters designed a progressive informatics platform called UNIFI®, which processes data from advanced and routine analyses to characterize sample compositions, using LC-MS technology. The platform enables a biotech laboratory to comprehensively and routinely acquire, process, and report LC and MS characterization data throughout the biotherapeutic development lifecycle.

“We have integrated our platform with solution kits and workflows, thus providing massive data integrity advantages to customers,” illustrates Craze. “UNIFI’s data mining and comparison capabilities enhance the ability to understand results, and to aggregate and manage data,” he adds. Furthermore, UNIFI provides organizations with the flexibility to deploy UNIFI-based systems within both regulated and non-regulated laboratory environments, while employing high resolution UPLC separations and high performance MS across the entire product lifecycle from discovery to development, and quality control.

UNIFI’s data mining and comparison capabilities enhance the ability to understand results with an unparalleled capability to aggregate and manage data

Since inception, Waters has become attuned to a culture of understanding and addressing client needs. For instance, one of their clients MacroGenics, Inc., a clinical-stage biopharmaceutical company, required a solution to reduce their risk of downstream failure, support their workflow, and provide highly accurate molecular weight information on intact molecules. Deploying the UNIFI platform in their environment helped the client to take their top-down analysis time from 1-3 weeks to 2-3 days. Waters scientists considered every aspect of peptide analysis—from chemistries, instrumentation, software, and methodology to usability, documentation, application support, and remote services—to create fit-for-purpose system solutions for peptide analysis and peptide mapping. As a result, MacroGenics reduced its peptide mapping cycle time from around 3-6 weeks to a single week.

Waters maintains a network of laboratories located around the globe so that customers can interact with the firm’s scientists and prototype implementations of their products. Moreover, Craze understands the need of planning Drug Metabolism and Pharmacokinetics (DMPK) (www.dmpk.waters.com) investments strategically to meet the future demands of laboratories that are expanding as organizations work to reinvigorate their drug product pipelines.

Waters is unique as a technology vendor in the pharmaceutical space, in that it has a very strong applied science base. A significant proportion of its global marketing team has previously worked directly within the pharmaceutical sector - some have even been personally responsible for running major DMPK functions. As such, Waters has a deep understanding of both the science involved in DMPK, the logistics associated with running an efficient operation, and a high degree of awareness towards innovation in the field, and industry dynamics.

Waters Corporation

Milford, MA

Andy Craze, Senior Director, Informatics Business

Develops innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance across various industries

Waters Corporation